CAPECITABINE PLUS OXALIPLATIN (CAPOX) VERSUS FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN STAGE III COLON CANCER: A COST-MINIMIZATION ANALYSIS BASED ON REAL WORLD COSTS IN THE NETHERLANDS

被引：0

作者：

van Gils, C. W. M. ^{[1
]}

de Groot, S. ^{[1
]}

Redekop, W. K. ^{[1
]}

Uyl-De Groot, C. A. ^{[1
]}

机构：

[1] Inst Med Techonol Assessment, Rotterdam, Netherlands

来源：

VALUE IN HEALTH | 2011年 / 14卷 / 07期

关键词：

D O I：

10.1016/j.jval.2011.08.1207

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A453 / A453

页数：1

共 50 条

[1] ECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE TREATMENT OF ADVANCED COLON-RECTUM CANCER IN CHINA
Chen, W.
VALUE IN HEALTH, 2010, 13 (07) : A263 - A263
[2] ECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE TREATMENT OF ADVANCED GASTRIC CANCER IN CHINA
Chen, W.
VALUE IN HEALTH, 2010, 13 (07) : A514 - A514
[3] COST-MINIMIZATION ANALYSIS OF XELOX (CAPECITABINE plus OXALIPLATIN) VERSUS FOLFOX-4 (5-FU/LV + OXALIPLATIN) AS ADJUVANT TREATMENT IN STAGE III COLON CANCER UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE
Prolla, G.
Borges, L. G.
Santos, E.
VALUE IN HEALTH, 2010, 13 (07) : A268 - A269
[4] PHARMACOECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS 5-FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE FIRST LINE TREATMENT OF METASTASIS COLORECTAL CANCER IN TAIWAN
Chen, H. H.
Chang, C. S.
Chen, L. T.
Chen, W. T.
Hsu, T. C.
Wang, J. Y.
Wen, C. Y.
VALUE IN HEALTH, 2009, 12 (07) : A278 - A278
[5] Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
Ducreux, Michel
Bennouna, Jaafar
Hebbar, Mohamed
Ychou, Marc
Lledo, Gerard
Conroy, Thierry
Adenis, Antoine
Faroux, Roger
Rebischung, Christine
Bergougnoux, Loic
Kockler, Leila
Douillard, Jean-Yves
INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (03) : 682 - 690
[6] Final results of a randomized comparison of infusional 5-fluorouracil/leucovorin plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) in metastatic colorectal carcinoma (MCRC)
Porschen, Rainer
Kubicka, S.
Grothey, A.
Grateven, U.
Kretzschmar, A.
Greil, R.
Freier, W.
Seufferlein, T.
Arkenau, Ht
Hinke, A.
Schmoll, Hj
Schmiegel, W.
GASTROENTEROLOGY, 2006, 130 (04) : A582 - A582
[7] Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer
Arnold, D.
STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (02) : 196 - 197
[8] Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
Haller, Daniel G.
Tabernero, Josep
Maroun, Jean
de Braud, Filippo
Price, Timothy
Van Cutsem, Eric
Hill, Mark
Gilberg, Frank
Rittweger, Karen
Schmoll, Hans-Joachim
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (11) : 1465 - 1471
[9] Phase III study of 5-fluorouracil/leucovorin plus oxaliplatin versus capecitabine plus oxaliplatin as first line therapy in patients with advanced colorectal cancer (ACRC)
Porschen, R
Arkenau, T
Kubicka, S
Schmoll, HJ
Seufferlein, T
Graeven, U
Grothey, A
GASTROENTEROLOGY, 2005, 128 (04) : A438 - A438
[10] Population-Based Cost-Minimization Analysis of CAPOX Versus Modified FOLFOX6 in the Adjuvant Treatment of Stage III Colon Cancer
Ho, Maria Y.
Chang, Albert Y.
Ruan, Jenny Y.
Cheung, Winson Y.
CLINICAL COLORECTAL CANCER, 2016, 15 (02) : 158 - 163

← 1 2 3 4 5 →